Stage 3 Type 1 Diabetes: Breakthrough T1D Funds New PRISE-hATG Trial

Big news in the diabetes world! Breakthrough T1D just dropped a major grant to fund a clinical trial targeting folks right at the tough Stage 3 of Type 1 Diabetes. The study, called PRISE-hATG, will test out a new drug named SAB-142. The idea? To help people freshly diagnosed, tackling the disease head-on when it’s still early. This could shake things up in how we fight T1D.

The Grant Announcement

So, Breakthrough T1D teamed up with SAB Biotherapeutics to make this happen. The money is headed to Dr. Michael J. Haller at the University of Florida, a top kid’s diabetes doc. He and his crew will run the PRISE-hATG trial, focusing on SAB-142. They’re zooming in on patients who are in that Stage 3 window — basically, from 100 days up to 2 years after their diagnosis. At this point, the body can’t make insulin anymore, so insulin shots become a must.

Let’s break it down in simple terms. Type 1 diabetes moves through stages. Stage 1 means you have the markers but your blood sugar is normal. Stage 2 means your blood sugar is off but you still don’t feel sick. Stage 3 is the classic diagnosis most people know—that’s when symptoms kick in and insulin therapy is a must-have. This trial is laser-focused on that narrow window right after diagnosis, hoping SAB-142 can actually slow the disease down and save some of those insulin-making cells.

Why This Study is a Big Deal

Here’s the kicker: once you hit Stage 3 T1D, insulin isn’t optional—it’s life or death. But insulin doesn’t cure anything; it just helps you live with it. Scientists have been chasing treatments that do more than just replace insulin. They want something that stops the immune system from attacking the body’s own cells. That’s exactly what SAB-142 aims to do. It’s a fully human anti-thymocyte globulin—yeah, a mouthful—but basically it swings at the immune attack directly.

Breakthrough T1D putting their weight behind this trial? Huge signal. They don’t throw money at just anything. This means SAB-142 has solid science behind it. For SAB Biotherapeutics, it’s a big thumbs-up for their tech. And for patients and families? It’s a real shot at hope. If this works, it could rewrite how doctors handle newly diagnosed T1D patients by adding a new tool right from the start. The long-term payoff could be massive.

Key Facts About the PRISE-hATG Study

• Breakthrough T1D, a big player in research and advocacy, awarded the grant.
• Dr. Michael J. Haller, the head honcho of Pediatric Endocrinology at the University of Florida, is leading the charge.
• SAB-142 is the drug tested—a fully human anti-thymocyte globulin made by SAB Biotherapeutics.
• The trial is for Stage 3 Type 1 Diabetes patients, specifically those diagnosed 100 days to 2 years ago.
• The main goal? To see if SAB-142 can calm the immune system and save the pancreas’ insulin-producing cells.

Looking Ahead: What Comes Next?

The game plan is set. With this grant, Dr. Haller’s team will kick off the PRISE-hATG trial. They’ll find patients who fit the bill, then give them either SAB-142 or a placebo to see what happens. From there, it’s all about watching closely—checking insulin production, blood sugar control (HbA1c), and how much insulin folks need. It’ll take some years to get the full picture, but the ball’s rolling.

This research is part of a bigger shift in how we approach diabetes: not just managing it but trying to change the course of the disease. If this goes well, it could pave the way for other treatments like it and also prove SAB’s platform works for treating autoimmune diseases. The science is tricky, but the goal is clear—a better life after getting that T1D diagnosis. Want to geek out more on the science? Check out this Related Source.

Frequently Asked Questions:

What is Stage 3 Type 1 Diabetes? Simply put, it’s the stage when symptoms show up because the immune system has wiped out enough insulin-producing cells that you need insulin to survive. Common signs include being thirsty all the time, peeing a lot, and unexpected weight loss.

How is SAB-142 supposed to work? It’s an immune system modulator. The hope is it hits pause on the body attacking its own insulin factories, letting some function hang on longer.

Who can join the PRISE-hATG trial? People diagnosed with Stage 3 Type 1 Diabetes within the last 100 days to 2 years. Specific rules are set by the research team at the University of Florida and the trial locations.

This grant isn’t just cash—it’s a symbol of hope. It backs a fresh idea at a crucial time in Type 1 Diabetes. For everyone affected, new trials like this keep the dream alive for better treatments and maybe, one day, a cure. The wait could totally be worth it.